{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138934","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.960113+00:00","generated_at":"2026-06-15T09:52:17.059535+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sensei Biotherapeutics reports Q1 2023 net loss of $10.2M; IND cleared for SNS-101 Phase 1/2 trial","bullets":["Cash, cash equivalents and marketable securities were $95.5M as of March 31, 2023; cash runway into H2 2025.","Net loss was $10.2M for Q1 2023, compared to $12.4M for Q1 2022; R&D expenses decreased to $5.2M.","FDA cleared IND for SNS-101 (conditionally active anti-VISTA antibody); Phase 1/2 trial enrollment and dosing expected mid-2023.","CRADA signed with NCI for VISTA research; SNS-102 and SNS-103 candidate selection on track for 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138934","json":"https://secwatch.observer/filing/0001193125-23-138934.json","markdown":"https://secwatch.observer/filing/0001193125-23-138934.md","text":"https://secwatch.observer/filing/0001193125-23-138934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/0001193125-23-138934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/d456403d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:52:17.059535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62b08a3b7fe76ad71631c5c772c4103465e4c429","claim":"Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.2 million.","evidence_excerpt":"Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/0001193125-23-138934-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$10.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}